The Korea Herald CENTER (0.0) Reliability: 7.0/10

Samsung Bioepis wins Japan approval for Stelara biosimilar

✍️ Ha Neul-Bit 📅 December 23, 2025 05:29 AM ⏱️ 1 min read 🕐 Scraped: December 23, 2025

Summary: Samsung Bioepis said Tuesday it has received approval from Japan’s Ministry of Health, Labor and Welfare for SB17, or ustekinumab, a biosimilar to the autoimmun

Samsung Bioepis said Tuesday it has received approval from Japan’s Ministry of Health, Labor and Welfare for SB17, or ustekinumab, a biosimilar to the autoimmune disease treatment Stelara.

Stelara, which targets the immune signaling proteins interleukin-

📰

Continue Reading on The Korea Herald

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

Ha Neul-Bit

Original Publisher

🌍 The Korea Herald

CENTER Bias (0.0)

Published Date

December 23, 2025 at 05:29 AM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.